Quantcast

Latest Benzamides Stories

2014-03-06 08:29:53

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present a comparison of the pharmacokinetic (PK) properties of Cynviloq and nab-paclitaxel (Abraxane(®)) at the 31(st )Annual Miami Breast Cancer Conference in Miami Beach, Florida. Highlights of the findings include new and historical data on PK bioequivalence of...

2014-03-03 08:32:55

SAN DIEGO, March 3, 2014 /PRNewswire/ -- Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®,...

2014-02-12 20:22:04

LOS ALTOS, Calif., Feb. 12, 2014 /PRNewswire/ -- Altos Therapeutics, LLC, was recently informed by the United States Patent and Trademark Office that its pending patent application covering Altos' dopamine D2/D3 receptor antagonists for treating gastrointestinal diseases will be granted. The patent that issues will broadly and specifically cover the company's drug candidates, their pharmaceutical compositions, and their use for treating a number of important gastrointestinal...

2014-02-11 08:32:10

SAN DIEGO, Feb. 11, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that it will present results of preclinical and Phase II clinical studies of Cynviloq(TM) in patients with metastatic pancreatic cancer at the Beaujon International Conference: Cutting Edge in Liver and Pancreatic Tumors in Paris, France on February 13, 2014. Highlights of the...

2014-02-10 16:26:58

SAN DIEGO, Feb. 10, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today the Company has obtained exclusive rights to Cynviloq(TM) (marketed as Genexol-PM(®) in South Korea and other countries) in Australia, Canada and Mexico from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation. Sorrento already has exclusive rights from Samyang for...

2014-01-27 12:29:27

Potential U.S. Commercialization Targeted for 2014 CHICAGO, Jan. 27, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid...

2014-01-23 20:22:19

HARBIN, China, Jan. 23, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today issued the following letter to shareholders: DEAR FELLOW SHAREHOLDERS: With the arrival of the Chinese New Year, I would like to take this opportunity to express my appreciation to all shareholders for the trust and...

2014-01-17 20:21:56

MELBOURNE, Australia, Jan. 17, 2014 /PRNewswire/ -- -- Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit -- First Phase III trial in metastatic pancreatic cancer to report three year survival rates[1] -- New standard of care for patients with metastatic pancreatic cancer A leading breast cancer drug, ABRAXANE(®)( )(nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for...

2014-01-13 04:20:46

SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has reached an agreement with Novartis to reacquire rights to two anti-cancer compounds -- pixantrone (PIXUVRI(®)) and paclitaxel poliglumex (Opaxio(TM)). Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date. Upon the effective date of termination, CTI will regain...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related